Información del artículo
Resumen
En los últimos años el interés en la amiloidosis cardíaca ha crecido exponencialmente. No obstante, es necesario mejorar en su conocimiento para optimizar los sistemas de detección precoz. Por lo tanto, es crucial incorporar instrumentos para mejorar la sospecha, el diagnóstico y el seguimiento de la amiloidosis cardíaca. En este sentido, diseñamos una herramienta siguiendo las distintas fases para alcanzar el diagnóstico de la amiloidosis cardíaca, así como un óptimo seguimiento: a) sospecha clínica, donde se pone en relieve la importancia de los «red flags» para sospecharla y activar el proceso diagnóstico; 2) diagnóstico, donde se desgrana principalmente el algoritmo diagnóstico; y 3) seguimiento de los pacientes confirmados. Se trata de una herramienta que será de gran utilidad para todos aquellos profesionales que atienden a pacientes con sospecha de amiloidosis cardíaca o enfermedad ya confirmada, para mejorar su detección precoz, así como optimizar su preciso diagnóstico y un óptimo seguimiento.
Palabras clave:
Amiloidosis cardíaca
Insuficiencia cardíaca
Red flags
Sospecha clínica
Diagnóstico precoz
Abstract
In recent years, the interest in cardiac amyloidosis has grown exponentially. However, there is a need to improve our understanding of amyloidosis in order to optimise early detection systems. Therefore, it is crucial to incorporate solutions to improve the suspicion, diagnosis and follow-up of cardiac amyloidosis. In this sense, we designed a tool following the different phases to reach the diagnosis of cardiac amyloidosis, as well as an optimal follow-up: a) clinical suspicion, where the importance of the “red flags” to suspect it and activate the diagnostic process is highlighted; 2) diagnosis, where the diagnostic algorithm is mainly outlined; and 3) follow-up of confirmed patients. This is a practical resource that will be of great use to all professionals caring for patients with suspected or confirmed cardiac amyloidosis, to improve its early detection, as well as to optimise its accurate diagnosis and optimal follow-up.
Keywords:
Cardiac amyloidosis
Heart failure
Red flags
Clinical suspicion
Early diagnosis
Artículo
Opciones para acceder a los textos completos de la publicación Revista Clínica Española
Socio
Si es usted socio de FESEMI siga los siguientes pasos:
Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.
Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":
>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<
Comprar
Bibliografía
[1]
T.A. McDonagh, M. Metra, M. Adamo, et al.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J, 42 (2021), pp. 3599-3726
[2]
D.H. Brahmbhatt, M.R. Cowie.
Remote Management of Heart Failure: An Overview of Telemonitoring Technologies.
Card Fail Rev, 5 (2019), pp. 86-92
[3]
P. Ponikowski, S.D. Anker, K.F. AlHabib, et al.
Heart failure: Preventing disease and death worldwide.
ESC Heart Fail, 1 (2014), pp. 4-25
[4]
F.J. Ruiz-Laiglesia, M. Sánchez-Marteles, J.I. Pérez-Calvo, et al.
Comorbidity in heart failure. Results of the Spanish RICA Registry.
QJM, 107 (2014), pp. 989-994
[5]
A. Groenewegen, F.H. Rutten, A. Mosterd, A.W. Hoes.
Epidemiology of heart failure.
Eur J Heart Fail, 22 (2020), pp. 1342-1356
[6]
N. Farré, E. Vela, M. Clèries, et al.
Medical resource use and expenditure in patients with chronic heart failure: A population-based analysis of 88 195 patients.
Eur J Heart Fail, 18 (2016), pp. 1132-1140
[7]
I. Sayago-Silva, F. García-López, J. Segovia-Cubero.
Epidemiology of heart failure in Spain over the last 20 years.
Rev Esp Cardiol (Engl Ed), 66 (2013), pp. 649-656
[8]
E. González-López, Á. López-Sainz, P. Garcia-Pavia.
Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope [Article in English, Spanish].
Rev Esp Cardiol (Engl Ed), 70 (2017), pp. 991-1004
[9]
S. Yun, J. González-Costello, F. Formiga.
Transthyretin amyloidosis: What we now see is just the tip of the iceberg [Article in Spanish].
Rev Esp Geriatr Gerontol, 55 (2020), pp. 255-257
[10]
J.D. Gillmore, M.S. Maurer, R.H. Falk, et al.
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Circulation, 133 (2016), pp. 2404-2412
[11]
M.S. Maurer, J.H. Schwartz, B. Gundapaneni, et al.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
N Engl J Med, 379 (2018), pp. 1007-1016
[12]
A. Ioannou, R.K. Patel, Y. Razvi, et al.
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis over the Course of 20 Years.
Circulation, 146 (2022), pp. 1657-1670
[13]
C. Rapezzi, G. Merlini, C.C. Quarta, et al.
Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types.
Circulation, 120 (2009), pp. 1203-1212
[14]
M.S. Maurer, P. Elliott, R. Comenzo, et al.
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.
Circulation, 135 (2017), pp. 1357-1377
[15]
S.F. Mohammed, S.A. Mirzoyev, W.D. Edwards, et al.
Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.
JACC Heart Fail, 2 (2014), pp. 113-122
[16]
E. González-López, M. Gallego-Delgado, G. Guzzo-Merello, et al.
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
Eur Heart J, 36 (2015), pp. 2585-2594
[17]
R. Ruiz-Hueso, P. Salamanca-Bautista, M.A. Quesada-Simón, et al.
Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure-Barriers and Opportunities for Improvement: The PREVAMIC Study.
J Clin Med, 12 (2023), pp. 2273
[18]
K. Lindmark, B. Pilebro, T. Sundström, et al.
Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.
ESC Heart Fail, 8 (2021), pp. 745-749
[19]
J.M. Griffin, J.L. Rosenthal, J.L. Grodin, et al.
ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review.
JACC CardioOncol, 3 (2021), pp. 488-505
[20]
M. Emdin, A. Aimo, C. Rapezzi, et al.
Treatment of cardiac transthyretin amyloidosis: An update.
Eur Heart J, 40 (2019), pp. 3699-3706
[21]
R.M. Witteles, S. Bokhari, T. Damy, et al.
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
JACC Heart Fail, 7 (2019), pp. 709-716
[22]
FESEMI. Fundación Española de la Sociedad Española de Medicina Interna [consultado 22 Feb 2024] Disponible en: https://www.fesemi.org/publicaciones/semi/protocolos/protocolo-actuacion amiloidosis-cardiaca
[23]
P. Garcia-Pavia, C. Rapezzi, Y. Adler, Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases, et al.
Eur Heart J, 42 (2021), pp. 1554-1568
[24]
F.L. Ruberg, M. Grogan, M. Hanna, et al.
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
J Am Coll Cardiol, 73 (2019), pp. 2872-2891
[25]
D. Brito, F.C. Albrecht, D.P. de Arenaza, et al.
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
Glob Heart, 18 (2023), pp. 59
[26]
J.M. Griffin, H. Rosenblum, M.S. Maurer.
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
Circ Res, 128 (2021), pp. 1554-1575
[27]
J.N. Nativi-Nicolau, C. Karam, S. Khella, et al.
Screening for ATTR amyloidosis in the clinic: Overlapping disorders, misdiagnosis, and multiorgan awareness.
Heart Fail Rev, 27 (2022), pp. 785-793
[28]
F. Kocher, A. Kaser, F. Escher, J. Doerler, et al.
Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis.
ESC Heart Fail, 7 (2020), pp. 3919-3928
[29]
C. Rapezzi, M. Lorenzini, S. Longhi, et al.
Cardiac amyloidosis: The great pretender.
Heart Fail Rev, 20 (2015), pp. 117-124
[30]
O.K. Siddiqi, F.L. Ruberg.
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Trends Cardiovasc Med, 28 (2018), pp. 10-21
[31]
A. Castano, D.L. Narotsky, N. Hamid, et al.
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Eur Heart J, 38 (2017), pp. 2879-2887
[32]
T.A. Treibel, M. Fontana, J.A. Gilbertson, et al.
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
Circ Cardiovasc Imaging, 9 (2016), pp. e005066
[33]
A. Galat, A. Guellich, D. Bodez, et al.
Aortic stenosis and transthyretin cardiac amyloidosis: The chicken or the egg?.
Eur Heart J, 37 (2016), pp. 3525-3531
[34]
J. Ternacle, L. Krapf, D. Mohty, et al.
Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week.
J Am Coll Cardiol, 74 (2019), pp. 2638-2651
[35]
C. Nitsche, P.R. Scully, K.P. Patel, et al.
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis.
J Am Coll Cardiol, 77 (2021), pp. 128-139
[36]
F. Formiga, L.S. Baeza, D. Chivite, et al.
Musculoskeletal co-morbidities in patients with transthyretin amyloid cardiomyopathy: A systematic review.
ESC Heart Fail, 11 (2024), pp. 662-671
[37]
J.N. Nativi-Nicolau, C. Karam, S. Khella, et al.
Screening for ATTR amyloidosis in the clinic: Overlapping disorders, misdiagnosis, and multiorgan awareness.
Heart Fail Rev, 27 (2022), pp. 785-793
[38]
A. Basdavanos, M.S. Maurer, L. Ives, et al.
Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies.
Am J Cardiol, 190 (2023), pp. 67-74
[39]
A. Milandri, A. Farioli, C. Gagliardi, S. Longhi, et al.
Carpal tunnel syndrome in cardiac amyloidosis: Implications for early diagnosis and prognostic role across the spectrum of aetiologies.
Eur J Heart Fail, 22 (2020), pp. 507-515
[40]
B.W. Sperry, B.A. Reyes, A. Ikram, et al.
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release.
J Am Coll Cardiol, 72 (2018), pp. 2040-2050
[41]
E.L. Fosbøl, R. Rørth, B.P. Leicht, et al.
Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes.
J Am Coll Cardiol, 74 (2019), pp. 15-23
[42]
F. Aus dem Siepen, S. Hein, S. Prestel, et al.
Carpal tunnel syndrome and spinal canal stenosis: Harbingers of transthyretin amyloid cardiomyopathy?.
Clin Res Cardiol, 108 (2019), pp. 1324-1330
[43]
J. Rubin, J. Alvarez, S. Teruya, et al.
Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: Can we identify affected patients earlier?.
Amyloid, 24 (2017), pp. 226-230
[44]
S.M. Gancarczyk, R.J. Strauch.
Carpal tunnel syndrome and trigger digit: Common diagnoses that occur “hand in hand”.
J Hand Surg Am, 38 (2013), pp. 1635-1637
[45]
T. Sueyoshi, M. Ueda, H.J. Jono, et al.
Wild-type transthyretin-derived amyloidosis in various ligaments and tendons.
Hum Pathol, 42 (2011), pp. 1259-1264
[46]
A. Triguero, J. González-Costello, S. López-Marne, et al.
Hand surgeons and amyloidosis specialists warning: Transthyretin-associated amyloidosis with bifid median nerve as a cause of bilateral carpal tunnel syndrome. A case report and literature review.
Eur J Orthop Surg Traumatol, 32 (2022), pp. 575-581
[47]
J. Huang, S. Zhao, Z. Chen, et al.
Contribution of Electrocardiogram in the Differentiation of Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy.
Int Heart J, 56 (2015), pp. 522-526
[48]
E. González-López, C. Gagliardi, F. Dominguez, et al.
Clinical characteristics of wild-type transthyretin cardiac amyloidosis: Disproving myths.
Eur Heart J, 38 (2017), pp. 1895-1904
[49]
P. García-Pavía, M.T. Tomé-Esteban, C. Rapezzi.
Amyloidosis. Also a heart disease [Article in Spanish].
Rev Esp Cardiol, 64 (2011), pp. 797-808
[50]
R.K. Cheng, A. Vasbinder, W.C. Levy, et al.
Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis.
J Am Heart Assoc, 10 (2021),
[51]
M. Grogan, C.G. Scott, R.A. Kyle, et al.
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
J Am Coll Cardiol, 68 (2016), pp. 1014-1020
[52]
S. Dorbala, S. Cuddy, R.H. Falk.
How to Image Cardiac Amyloidosis: A Practical Approach.
JACC Cardiovasc Imaging, 13 (2020), pp. 1368-1383
[53]
M. Boldrini, F. Cappelli, L. Chacko, et al.
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis.
JACC Cardiovasc Imaging, 13 (2020), pp. 909-920
[54]
M.S. Maurer, S. Bokhari, T. Damy, et al.
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Circ Heart Fail, 12 (2019), pp. e006075
[55]
J.N. Dungu, L.J. Anderson, C.J. Whelan, et al.
Cardiac transthyretin amyloidosis.
Heart, 98 (2012), pp. 1546-1554
[56]
S. Khanna, I. Wen, A. Bhat, et al.
The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update.
Front Cardiovasc Med, 7 (2020), pp. 590557
[57]
B.W. Sperry, A. Ikram, R. Hachamovitch, et al.
Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
J Am Coll Cardiol, 67 (2016), pp. 2941-2948
[58]
T.E. Long, O.S. Indridason, R. Palsson, et al.
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
Blood Cancer J, 12 (2022), pp. 133
[59]
E. Perugini, P.L. Guidalotti, F. Salvi, et al.
Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.
J Am Coll Cardiol, 46 (2005), pp. 1076-1084
[60]
F.J. de Haro-del Moral, A. Sánchez-Lajusticia, M. Gómez-Bueno, et al.
Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype [Article in English, Spanish].
Rev Esp Cardiol (Engl Ed), 65 (2012), pp. 440-446
[61]
J.M. Saad, A.I. Ahmed, D. Anugula, et al.
It Takes a Village: Multimodality Imaging of Cardiac Amyloidosis.
Methodist DeBakey Cardiovasc J, 18 (2022), pp. 47-58
[62]
M.A. Gertz, M.D. Benson, P.J. Dyck, et al.
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
J Am Coll Cardiol, 66 (2015), pp. 2451-2466
[63]
J.D. Gillmore, M.M. Reilly, C.J. Coats, et al.
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
Adv Ther, 39 (2022), pp. 2292-2301
[64]
D. Adams, Y. Ando, J.M. Beirão, et al.
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
J Neurol, 268 (2021), pp. 2109-2122
[65]
J.P. Donnelly, M. Hanna.
Cardiac amyloidosis: An update on diagnosis and treatment.
Cleve Clin J Med, 84 (2017), pp. 12-26
[66]
M.A. Gertz, M.L. Mauermann, M. Grogan, et al.
Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Brain Behav, 9 (2019), pp. e01371
[67]
I. Conceição, A. González-Duarte, L. Obici, et al.
Red-fla’ symptom clusters in transthyretin familial amyloid polyneuropathy.
J Peripher Nerv Syst, 21 (2016), pp. 5-9
[68]
F.A. Barroso, T. Coelho, A. Dispenzieri, et al.
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Amyloid, 29 (2022), pp. 175-183
[69]
P. Díez-Villanueva, A. Arizá-Solé, M.T. Vidán, et al.
Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the Assessment of Frailty in Elderly Patients With Heart Disease [Article in English, Spanish].
Rev Esp Cardiol (Engl Ed), 72 (2019), pp. 63-71
[70]
M.M. Kittleson, F.L. Ruberg, A.V. Ambardekar, et al.
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.
J Am Coll Cardiol, 81 (2023), pp. 1076-1126
[71]
N. Bumma, R. Kahwash, S.V. Parikh, et al.
Multidisciplinary amyloidosis care in the era of personalized medicine.
Front Neurol, 13 (2022), pp. 935936
